Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) - PubMed (original) (raw)

Comment

. 2004 Mar 17;96(6):487-8.

doi: 10.1093/jnci/djh081.

Michael Quinn, Tate Thigpen, Andreas du Bois, Eric Pujade-Lauraine, Anders Jakobsen, Elizabeth Eisenhauer, Satoru Sagae, Kathryn Greven, Ignace Vergote, Andres Cervantes, Jan Vermorken

• PMID: 15026475
• DOI: 10.1093/jnci/djh081

Comment

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)

Gordon J S Rustin et al. J Natl Cancer Inst. 2004.

No abstract available

PubMed Disclaimer

Comment in

• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
  Taylor PT, Haverstick D. Taylor PT, et al. J Natl Cancer Inst. 2005 Jan 19;97(2):151; author reply 152. doi: 10.1093/jnci/dji027. J Natl Cancer Inst. 2005. PMID: 15657346 No abstract available.

Comment on

• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
  Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. Therasse P, et al. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205. J Natl Cancer Inst. 2000. PMID: 10655437

Similar articles

• Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
  Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB. Vergote I, et al. J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5. doi: 10.1093/jnci/92.18.1534. J Natl Cancer Inst. 2000. PMID: 10995813 No abstract available.
• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
  Taylor PT, Haverstick D. Taylor PT, et al. J Natl Cancer Inst. 2005 Jan 19;97(2):151; author reply 152. doi: 10.1093/jnci/dji027. J Natl Cancer Inst. 2005. PMID: 15657346 No abstract available.
• Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
  Pisal N, Sindos M, Singer A. Pisal N, et al. J Natl Cancer Inst. 2003 Feb 19;95(4):331; author reply 331-2. doi: 10.1093/jnci/95.4.331. J Natl Cancer Inst. 2003. PMID: 12591991 No abstract available.
• Clinical practice. Screening for ovarian cancer.
  Clarke-Pearson DL. Clarke-Pearson DL. N Engl J Med. 2009 Jul 9;361(2):170-7. doi: 10.1056/NEJMcp0901926. N Engl J Med. 2009. PMID: 19587342 Review. No abstract available.
• Risk of malignancy in sonographically confirmed ovarian tumors.
  Miller RW, Ueland FR. Miller RW, et al. Clin Obstet Gynecol. 2012 Mar;55(1):52-64. doi: 10.1097/GRF.0b013e31824970cf. Clin Obstet Gynecol. 2012. PMID: 22343229 Review.

Cited by

• A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis.
  Liu Y, Huang Y, Li J, Wan S, Jiang N, Yang J, Chiampanichayakul S, Tima S, Anuchapreeda S, Wu J. Liu Y, et al. Front Pharmacol. 2022 Nov 10;13:1010626. doi: 10.3389/fphar.2022.1010626. eCollection 2022. Front Pharmacol. 2022. PMID: 36438821 Free PMC article.
• First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
  Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. Yap TA, et al. Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28. Cancer Discov. 2021. PMID: 32988960 Free PMC article.
• Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
  Pearl ML, Dong H, Tulley S, Zhao Q, Golightly M, Zucker S, Chen WT. Pearl ML, et al. Gynecol Oncol. 2015 May;137(2):229-38. doi: 10.1016/j.ygyno.2015.03.002. Epub 2015 Mar 11. Gynecol Oncol. 2015. PMID: 25769657 Free PMC article.
• Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.
  von Gruenigen VE, Frasure HE, Smith DA, Fusco NL, Eaton SM, DeBernardo RL, Heugel AM, Waggoner SE. von Gruenigen VE, et al. Anticancer Drugs. 2012 Aug;23(7):724-30. doi: 10.1097/CAD.0b013e32835396d4. Anticancer Drugs. 2012. PMID: 22555194 Free PMC article. Clinical Trial.
• A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.
  Green DS, Nunes AT, David-Ocampo V, Ekwede IB, Houston ND, Highfill SL, Khuu H, Stroncek DF, Steinberg SM, Zoon KC, Annunziata CM. Green DS, et al. J Transl Med. 2018 Jul 16;16(1):196. doi: 10.1186/s12967-018-1569-5. J Transl Med. 2018. PMID: 30012146 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information